Non-specific irreversible 89Zr-mAb uptake in tumours: evidence from biopsy-proven target-negative tumours using 89Zr-immuno-PET
Abstract Background Distribution of mAbs into tumour tissue may occur via different processes contributing differently to the 89Zr-mAb uptake on PET. Target-specific binding in tumours is of main interest; however, non-specific irreversible uptake may also be present, which influences quantification...
Main Authors: | Jessica E. Wijngaarden, Yvonne W. S. Jauw, Gerben J. C. Zwezerijnen, Berlinda J. de Wit-van der Veen, Daniëlle J. Vugts, Josée M. Zijlstra, Guus A. M. S. van Dongen, Ronald Boellaard, C. Willemien Menke-van der Houven van Oordt, Marc C. Huisman |
---|---|
Format: | Article |
Language: | English |
Published: |
SpringerOpen
2024-02-01
|
Series: | EJNMMI Research |
Subjects: | |
Online Access: | https://doi.org/10.1186/s13550-024-01079-5 |
Similar Items
-
Potential and pitfalls of 89Zr-immuno-PET to assess target status: 89Zr-trastuzumab as an example
by: Marc C. Huisman, et al.
Published: (2021-08-01) -
How to obtain the image-derived blood concentration from 89Zr-immuno-PET scans
by: Jessica E. Wijngaarden, et al.
Published: (2024-02-01) -
Optimal imaging time points considering accuracy and precision of Patlak linearization for 89Zr-immuno-PET: a simulation study
by: Jessica E. Wijngaarden, et al.
Published: (2022-09-01) -
<sup>89</sup>Zr-Immuno-PET with Immune Checkpoint Inhibitors: Measuring Target Engagement in Healthy Organs
by: Iris H. C. Miedema, et al.
Published: (2023-11-01) -
3D Convolutional Neural Network-Based Denoising of Low-Count Whole-Body <sup>18</sup>F-Fluorodeoxyglucose and <sup>89</sup>Zr-Rituximab PET Scans
by: Bart M. de Vries, et al.
Published: (2022-02-01)